Research Article | Open Access
T. Jasinska, A. Grzanka, E. Machura, A. Kasperska-Zajac, "Is Delayed Pressure Urticaria Associated with Increased Systemic Release of sCD40L?", BioMed Research International, vol. 2013, Article ID 823798, 4 pages, 2013. https://doi.org/10.1155/2013/823798
Is Delayed Pressure Urticaria Associated with Increased Systemic Release of sCD40L?
Background. Elevated levels of soluble CD40 Ligand (sCD40L) were found in serum but not in plasma of patients with chronic spontaneous urticaria (CU). What is important is that sCD40L has proinflammatory properties, and its elevated plasma level may indicate increased risk of cardiovascular events. These observations should stimulate further evaluation of sCD40L in different forms of urticaria. Aim. In the present study, sCD40L plasma level was investigated in delayed pressure urticaria (DPU). Methods. As platelets are predominant and variable sources of sCD40L, we investigated sCD40L concentration in platelet-poor plasma (PPP), which seems the best way to minimize the potential contribution of these cells to the ligand level. Results. Plasma sCD40L concentration was significantly increased in the DPU group compared to the healthy controls. Conclusions. It seems that DPU is associated with increased systemic release of sCD40L, which is believed to derive predominantly from activated platelets. The present study as well as the earlier contributions suggest that distinct cells activity, including platelets, may be identified in different types of urticaria.
Chronic spontaneous urticaria (CU) and delayed pressure urticaria (DPU) are associated with systemic inflammatory reaction that is called acute-phase response (APR) as well as other signs of inflammatory activity [1–4].
It has been documented that platelets contribute to immune-inflammatory processes [5, 6]. However, data regarding behaviour of these cells and their mediators in different forms of urticaria are very scarce.
CD40L is the transmembrane protein of the tumor necrosis factor family  expressed by different cell types, including lymphocytes , mast cells, basophils , and platelets [10, 11], and it is subsequently cleaved generating a circulating soluble form of CD40L (sCD40L). Circulating sCD40L is believed to derive predominantly from activated platelets and therefore may reflect platelet activation [10, 11].
It has been demonstrated that serum sCD40L concentration is significantly increased in CU patients as compared to healthy subjects, suggesting that sCD40L may be involved in immune activation observed in this disease [15, 16]. On the contrary, we did not find significant differences in sCD40L concentration in platelet-poor plasma (PPP) between CU patients and the healthy subjects, indicating that free circulating sCD40L may not be elevated in CU patients . Taken together, this may confirm that serum may be better to assess a total pool of sCD40L stored in platelets and other cells; on the other hand, PPP is more useful to measure free circulating levels of sCD40L in vivo [18, 19].
Taking into account both DPU as a distinct form of urticaria and the contribution of platelets to inflammation in DPU, it seems interesting to investigate release reaction of sCD40L in the disease. In the present study, sCD40L plasma level was investigated in DPU.
Eighteen symptomatic patients (11 men and 7 women) of age range 26–44 years (the median age 37 years), nine patients with pure DPU (DPU alone subgroup) and nine patients with concomitant chronic spontaneous urticaria (DPU/CU subgroup), were enrolled into the study. All identified causes of urticaria, including autoreactivity and concomitant diseases had been excluded. Seven patients suffered from severe DPU, urticarial lesions still elicited even under slight pressure. In the remaining 11, less extensive urticarial lesions were observed during physical examination.
At least three weeks before the examination, the patients with severe disease ceased to take corticosteroids (except for 1 patient). The antihistamines were withdrawn 3-4 days before the study.
The control group consisted of 27 nonsmoking healthy patients (12 females and 15 males; the median age was 36 years, range 27–43) without any medication.
The Local Ethics Commission approved this study, and written informed consent was obtained from all participating subjects.
2.1. Blood Sampling and Plasma CD40L Measurement
Whole blood was obtained in the morning (7.00 a.m. to 8.00 a.m., in the fasting state) after 25-minute rest at slight or no stasis from an antecubital vein into EDTA (theophylline, adenosine, and dipyridamole) tubes then immediately placed in melting ice. For platelet-poor plasma (PPP) preparation the samples were centrifuged at 1000 ×g for 15 minutes at 4°C, followed by an additional centrifugation at 10000 ×g for 10 min to ensure elimination of platelets. PPP samples were stored at –80°C until analysis. Quantification of sCD40L was performed with a commercial enzyme-linked immunosorbent assay (ELISA) kit (R&D System, Abingdon, United Kingdom) according to the manufacturer’s instructions.
Each sample was measured in duplicate. At our laboratory, the intra-assay and interassay coefficients of variation were <8%.
The number of peripheral blood platelets was measured by the automated haematology analyser.
2.2. Statistical Analysis
Data are presented as median and quartile ranges. Kruskal-Wallis variance analysis was used for screening differences between the groups. Mann-Whitney test was used to compare data between the patient groups and the healthy controls. Spearman’s rank test was performed for correlations. values below 0.05 were considered significant.
Plasma sCD40L concentrations were significantly higher in DPU as a whole and DPU without concomitant CU (DPU alone) as compared with the healthy subjects (median (quartile range): 87.9 (49.3–122.4), 88.6 (53.1–138.2), and 24.2 (12.2–93.3) pg/mL, resp.) (Figure 1). No significant differences were found between the three groups in platelet count (data not shown).
No significant correlations were observed between CD40L concentrations and platelet count and CRP concentration (, and , , resp.).
To the best of our knowledge, this study is the first to provide important information regarding increased plasma sCD40L levels in DPU. However, data regarding behaviour of these cells and their mediators in different forms of urticaria are very scarce [20, 21].
Elevated serum level of soluble sCD40L was found in patients with CU, suggesting that in this disease sCD40L may be involved in immune activation [15, 16]. On the other hand, we have not found any significant differences in plasma sCD40L levels in CU patients . Taken together, the results suggests that total pool of sCD40L stored in platelets and other cells is increased in CU, but free circulating sCD40L is not elevated.Contrary to the previous results, we observed increased plasma concentration of sCD40L in DPU patients. The discrepancy of the results is unclear. Firstly, DPU is a distinct form of urticaria characterized by deep inflammatory infiltrate and systemic symptoms.
Secondly, changes in platelet activity have been reported in DPU indicating on enhanced platelet activity measured by PF-4 and beta-thromboglobulin plasma concentration . The translocation of CD40L seems to coincide with the release of α-granule contents including platelet factor 4 (PF-4). In addition, it is estimated that 95% of the circulating sCD40L is derived from platelets. However, platelet may not be the sole source of sCD40L in DPU, and other cells may contribute to the increased circulating level [18, 19].
The mechanisms leading to platelet activation and/or increased sCD40L release in DPU were not identified in this study. Circulating platelets are highly reactive to exogenous and endogenous stimuli, including cytokines and immune mediators. Expression of CD40L is induced by proinflammatory stimuli, such as IL-3 and tumor necrosis factor-alpha (TNF-α), which are known to increase in DPU . On the other hand, it seems that APR, manifested by increased concentration of CRP, does not play a direct role in upregulation of a transmembrane sCD40L release. On the one hand, platelet hyperactivity has not been observed in CU which is known to be associated with APR . In addition, there was no correlation between sCD40L and CRP concentrations in DPU.
CD40L or its circulating soluble counterpart (sCD40L) may upregulate inflammatory and immune responses [12–14]. Therefore, we speculate that the protein has proinflammatory activity in DPU and contributes to amplification of the urticarial inflammation.
What is important is that elevated plasma sCD40L and CRP concentrations may indicate the increased risk of cardiovascular events [24, 25]. The observations made recently and our results suggest an increased risk of cardiovascular events in severe and long-lasting DPU, which might result from increased concentration of these biomarkers.
Because of the small study sample, future research is needed to prove release of sCD40L from platelets and to get more insights into the mechanisms of platelet activation and sCD40L function in DPU.
Our results indicate that DPU is associated with increased circulating sCD40L level, which is believed to derive predominantly from activated platelets. These findings may confirm ongoing platelet activation in DPU, manifested by increased chemokines and sCD40L release into the circulation. The present study as well as the earlier contribution suggest that distinct cells activity, including platelets, may be identified in different types of urticaria, similarly to that reported in atopic diseases .
Conflict of Interests
The authors declare that they have no conflict of interests.
This study was supported by a research Grant from the Committee for Scientific Research (NN-1-131/12).
- A. Kasperska-Zajac, J. Sztylc, E. Machura, and G. Jop, “Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients,” Clinical and Experimental Allergy, vol. 41, no. 10, pp. 1386–1391, 2011.
- A. Kasperska-Zajac, A. Grzanka, E. Czecior, M. Misiolek, B. Rogala, and E. Machura, “Acute phase inflammatory markers in patients with non-steroidal anti-inflammatory drugs (NSAIDs)-induced acute urticaria/angioedema and after aspirin challenge,” Journal of the European Academy of Dermatology and Venereology, vol. 27, no. 8, pp. 1048–1052, 2012.
- A. Kasperska-Zajac, “Acute phase response in chronic urticaria,” Journal of the European Academy of Dermatology and Venereology, vol. 26, no. 6, pp. 665–672, 2012.
- A. Kasperska-Zajac, T. Jasinska, A. Grzanka, and A. Kowalik-Sztylc, “Markers of systemic inflammation in delayed pressure urticaria,” International Journal of Dermatology, vol. 53, pp. 309–310, 2013.
- A. Kasperska-Zajac and B. Rogala, “Platelet activation during allergic inflammation,” Inflammation, vol. 30, no. 5, pp. 161–166, 2007.
- A. Kasperska-Zaj̧c and B. Rogala, “Platelet function in anaphylaxis,” Journal of Investigational Allergology and Clinical Immunology, vol. 16, no. 1, pp. 1–4, 2006.
- R. M. Locksley, N. Killeen, and M. J. Lenardo, “The TNF and TNF receptor superfamilies: integrating mammalian biology,” Cell, vol. 104, no. 4, pp. 487–501, 2001.
- D. Graf, S. Müller, U. Korthäuer, C. van Kooten, C. Weise, and R. A. Kroczek, “A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation,” European Journal of Immunology, vol. 25, no. 6, pp. 1749–1754, 1995.
- J.-F. Gauchat, S. Henchoz, G. Mazzei et al., “Induction of human IgE synthesis in B cells by mast cells and basophils,” Nature, vol. 365, no. 6444, pp. 340–343, 1993.
- P. André, L. Nannizzi-Alaimo, S. K. Prasad, and D. R. Phillips, “Platelet-derived CD40L: the switch-hitting player of cardiovascular disease,” Circulation, vol. 106, no. 8, pp. 896–899, 2002.
- J. E. Freedman, “CD40-CD40L and platelet function: beyond hemostasis,” Circulation Research, vol. 92, no. 9, pp. 944–946, 2003.
- V. Henn, J. R. Slupsky, M. Gräfe et al., “CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells,” Nature, vol. 391, no. 6667, pp. 591–594, 1998.
- I. S. Grewal and R. A. Flavell, “The CD40 ligand: at the center of the immune universe?” Immunologic Research, vol. 16, no. 1, pp. 59–70, 1997.
- R. P. Phipps, “Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 6930–6932, 2000.
- J. V. Garmendia, M. Zabaleta, I. Blanca, N. E. Bianco, and J. B. de Sanctis, “Total and biologically active serum-soluble CD154 in patients with chronic idiopathic urticaria,” Allergy and Asthma Proceedings, vol. 25, no. 2, pp. 121–125, 2004.
- A. Szegedi, B. Irinyi, M. Gál et al., “Significant correlation between the CD63 assay and the histamine release assay in chronic urticaria,” British Journal of Dermatology, vol. 155, no. 1, pp. 67–75, 2006.
- T. Jasinska and A. Kasperska-Zajac, “Soluble CD40 ligand is not elevated in plasma of patients with chronic spontaneous urticaria,” British Journal of Dermatology, vol. 167, no. 2, pp. 450–452, 2012.
- J. Thom, G. Gilmore, Q. Yi, G. J. Hankey, and J. W. Eikelboom, “Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma,” Journal of Thrombosis and Haemostasis, vol. 2, no. 11, pp. 2067–2069, 2004.
- S. Riondino, F. Martini, F. La Farina, A. Spila, F. Guadagni, and P. Ferroni, “Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions,” Clinical Biochemistry, vol. 43, no. 7-8, pp. 666–670, 2010.
- A. Kasperska-Zajac, B. Rogala, and M. Nowakowski, “Assessment of platelet activity as expressed by plasma levels of platelet factor 4 and β-thromboglobulin in patients with chronic idiopathic urticaria,” Experimental Dermatology, vol. 14, no. 7, pp. 515–518, 2005.
- A. Kasperska-Zajac, Z. Brzoza, and B. Rogala, “Platelet function in cutaneous diseases,” Platelets, vol. 19, no. 5, pp. 317–321, 2008.
- A. Kasperska-Zajac, Z. Brzoza, and B. Rogala, “Increased concentration of platelet-derived chemokinesin serum of patients with delayed pressure urticaria,” European Cytokine Network, vol. 19, no. 2, pp. 89–91, 2008.
- B. Hermes, A.-K. Prochazka, N. Haas, K. Jurgovsky, M. Sticherling, and B. M. Henz, “Upregulation of TNF-α and IL-3 expression in lesional and uninvolved skin in different types of urticaria,” Journal of Allergy and Clinical Immunology, vol. 103, no. 2, pp. 307–314, 1999.
- U. Schönbeck, N. Varo, P. Libby, J. Buring, and P. M. Ridker, “Soluble CD40L and cardiovascular risk in women,” Circulation, vol. 104, no. 19, pp. 2266–2268, 2001.
- J. Danesh, J. G. Wheeler, G. M. Hirschfield et al., “C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1387–1397, 2004.
- A. Kasperska-Zajac and B. Rogala, “Markers of platelet activation in plasma of patients suffering from persistent allergic rhinitis with or without Asthma symptoms,” Clinical and Experimental Allergy, vol. 35, no. 11, pp. 1462–1465, 2005.
Copyright © 2013 T. Jasinska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.